Chemokine receptor antagonists: part 2. (Q37481304)

20 August 2017

1 reference

title

Chemokine receptor antagonists: part 2. (English)

1 reference

20 August 2017

James E Pease

1

1 reference

20 August 2017

Richard Horuk

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

Expert Opinion on Therapeutic Patents

20 August 2017

published in

1 reference

20 August 2017

volume

19

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

199-221

1 reference

Molecular cloning and functional expression of a new human CC-chemokine receptor gene

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Expression of Chemokine Receptors by Lung T Cells from Normal and Asthmatic Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Expression of chemokines and chemokine receptors during human renal transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Co-receptors for HIV-1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

CCR5 antagonists as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N'-diphenylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailabl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Orally bioavailable competitive CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Identification of CCR8, the receptor for the human CC chemokine I-309

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

The transient expression of C-C chemokine receptor 8 in thymus identifies a thymocyte subset committed to become CD4+ single-positive T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Molecular cloning and RNA expression of two new human chemokine receptor-like genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

CCL1-CCR8 Interactions: An Axis Mediating the Recruitment of T Cells and Langerhans-Type Dendritic Cells to Sites of Atopic Skin Inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Oxazolidinones as novel human CCR8 antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Requirement of the chemokine receptor CXCR3 for acute allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Design and optimization of imidazole derivatives as potent CXCR3 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Identification and structure-activity relationships of 1-aryl-3-piperidin-4-yl-urea derivatives as CXCR3 receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Development of CXCR3 antagonists. Part 2: Identification of 2-amino(4-piperidinyl)azoles as potent CXCR3 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Development of CXCR3 antagonists. Part 4: discovery of 2-amino-(4-tropinyl)quinolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Identification and initial evaluation of 4-N-aryl-[1,4]diazepane ureas as potent CXCR3 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Discovery of small molecule CXCR4 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Configurationally restricted bismacrocyclic CXCR4 receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

CCR1 antagonists in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

The clinical potential of chemokine receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Development of a virtual screening method for identification of "frequent hitters" in compound libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

The pharmacology and use of H1-receptor-antagonist drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Inhaled glucocorticoids for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Novel ligands for the chemokine receptor-3 (CCR3): a receptor-modeling study based on 5D-QSAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Structure-activity relationships of 2-(benzothiazolylthio)acetamide class of CCR3 selective antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Discovery of a novel CCR3 selective antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Evaluation of a series of bicyclic CXCR2 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

Crystal structure of the human beta2 adrenergic G-protein-coupled receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

I want a new drug: G-protein-coupled receptors in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

CCR5 is characteristic of Th1 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802641353

10.1517/13543770802641353

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference